This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

UKPDS 39 trial

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The UKPDS 39 trial aimed to determine whether a beta-blocker or an angiotensin converting enzyme inhibitor had a specific advantage or disadvantage in the prevention of macrovascular and microvascular complications of type 2 diabetes.

The trial randomly assigned patients to tight control of blood pressure (aim <150/85 mmHg) with captopril or atenolol.

Reference:

  • 1) UK Prospective Diabetes Study Group (1998). Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complication in type 2 diabetes: UKPDS 39. BMJ, 317, 713-720.

Related pages

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.